DelveInsight Business Research LLP

DelveInsight’s “Acute Gout Flare Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Acute Gout Flare, historical and forecasted epidemiology as well as the Acute Gout Flare market trends in the United States, EU4 (Germany, Spain, Italy, France), and the UK, and Japan.

Acute Gout Flare Overview

Gout is a  form of inflammatory arthritis that is triggered by the crystallization of monosodium urate (MSU) inside the joints and is preceded by hyperuricemia. Gout progresses in 4 stages: Asymptomatic hyperuricemia, Acute gout flare/attack, inter-critical period, and if left untreated the disease reaches Chronic tophaceous gout. In general, Gout is a manageable disease if diagnosed and treated properly. Gout flares lead to substantial morbidity by causing severe pain, reduced quality of life, and decreased physical function as the patients experience symptoms such as severe pain and inflammation in one or more joints. Epidemiology studies show that Gout has become more prevalent over the past few decades, affecting over 3% of adults in the US.

Acute Gout Flare  Epidemiology Insights

• The general prevalence of gout is 1–4% of the general population. By gender, men are more predisposed to gout than females. In Western countries, it occurs in 3–6% in men and 1–2% of women. In some countries, prevalence may increase up to 10%. Prevalence rises up to 10% in men and 6% in women more than 80 years old. The annual incidence of gout is 2.68 per 1000 persons. It occurs in men 2–6 folds more than women. The worldwide incidence of gout increases gradually due to poor dietary habits such as fast foods, lack of exercise, increased incidence of obesity, and metabolic syndrome. 

• As per the National Health and Nutrition Examination Survey (NHANES), the prevalence of gout was 3.9% among US adults, which corresponds to an estimated 9.2 million adults in 2015–2016.

• As per NHANES, the prevalence of Gout in the US men was 5.2% (5.9 million) and 2.7% (3.3 million) among women, in 2015-2016. The disease prevalence increased with age, with the lowest gout prevalence (0.7% or 0.6 million) in individuals aged 20 to 39 years and the highest (8.7% or 1.0 million) in individuals aged 80 years or older

• The EPISER 2016 (Study of the Prevalence of rheumatic diseases in the adult population) study in Spain, says that gout has a prevalence of more than 2.6% in the Spanish adult population

• In  2015, Gout affected more than 8 million Americans. 

Click here to learn more about the Acute Gout Flare Market Landscape

The Report Covers the Acute Gout Flare  Epidemiology Segmented by:

• Acute Gout Flare Incident Cases 

• Acute Gout Flare Age-Specific Cases 

• Acute Gout Flare Gender-Specific Cases 

Acute Gout Flare Market Outlook 

The increasing prevalence of Acute Gout Flare in almost all 7MM, rise in neonatal screening and diagnostic awareness, new upcoming novel gene-based therapies, and regulatory programs to fasten the lab-to-market process are projected to propel the market growth during the forecast period. However, the need for infant patients to test gene-based therapies and the rare nature of Acute Gout Flare is likely to hamper the clinical development of emerging therapies. Many emerging therapies are expected to cost a premium annual cost per patient in the Acute Gout Flare market and hence, approaching reimbursement proactively can have a positive impact in ensuring successful product launch in this market.

Acute Gout treatment includes first-line treatment with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) or COX-2 Inhibitors, Anti-inflammatory Corticosteroids, Colchicine or local steroid injections. Immediate therapy for acute gout attacks aims to reduce pain and promote a full, early resolution. In most cases, acute attacks are followed by recurrent attacks with decreasing inter-critical periods, leading to Chronic Gout. Chronic gout manifests by chronic synovitis, bony erosions, cartilage damage, and tophi formation.

The EULAR recommends considering IL-1 blockers for the management of gout flares in patients with frequent flares contraindicated to NSAIDs, colchicine, and steroids (oral or injectable). Canakinumab, a long-lasting antibody to IL-1 beta, has been approved by the European Medical Agency, following 2 RCT trials against intramuscular triamcinolone acetonide. In addition, Anakinra, an IL-1 receptor antagonist, is used off-label in these cases. ULDs (Urate Lowering Drugs) are used to maintain uric acid levels in the blood.

Key Companies Working in the Acute Gout Flare Market

• Olatec Therapeutics

• Dyve Biosciences

And many others 

Acute Gout Flare Therapies Covered and Analyzed in the Report

• Dapansutrile

• DYV700

And many others 

Learn more about the Key Companies and Emerging Therapies in the Acute Gout Flare Market

 Table of Contents 

1. Key Insights 

2. Acute Gout Flare Introduction 

3. Executive Summary of Acute Gout Flare           

4. Disease Background and Overview

5. Epidemiology and patient population

6. Acute Gout Flare Emerging Therapies

7. Acute Gout Flare Market Outlook

8. Market Access and Reimbursement of Therapies

9. Market Drivers 

10. Market Barriers 

11. Appendix

12. Report Methodology

13. DelveInsight Capabilities

14. Disclaimer

Learn about the detailed offerings of the report @ Acute Gout Flare Market Outlook

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services